TALPHERA, INC. (TLPH) - Dilution Analysis

10-Q filing | 51.9M shares outstanding

10-K filing | 50.0M shares outstanding

8-K filing: Talphera, Inc. completed the third closing of a private placement, issuing 639,931 shares of common stock at $0.586 per share and pre-funded warrants to purchase up to 6,399,316 shares at $0.585 per warrant.

10-Q filing | 46.6M shares outstanding

S-3 filing: This S-3 filing registers for resale up to 1,023,890 shares of common stock and 1,706,484 shares of common stock issuable upon exercise of pre-funded warrants by selling stockholders who acquired these securities through a prior private placement.

S-3 filing: This prospectus relates to the proposed resale from time to time by the selling stockholders of up to 25,036,360 shares of common stock and 5,845,455 shares of common stock issuable upon exercise of pre-funded warrants.

8-K filing: Talphera, Inc. issued and sold 25,036,360 shares of common stock at $0.55 per share and pre-funded warrants to purchase up to 5,845,455 shares of common stock at $0.549 per share in a private placement, resulting in gross proceeds of approximately $17 million. ($16.98M proceeds)

10-Q filing | 20.5M shares outstanding

10-Q filing | 20.5M shares outstanding

S-3 filing: This prospectus relates to the proposed resale from time to time by the selling stockholders of up to 3,405,118 shares of common stock and 4,999,316 shares of common stock issuable upon exercise of pre-funded warrants.

8-K filing: Talphera, Inc. entered into a securities purchase agreement for a private placement involving the issuance and sale of common stock and pre-funded warrants in three tranches, with the first closing on April 2, 2025, resulting in gross proceeds of approximately $4.9 million. ($4.9M proceeds)

10-K filing | 17.1M shares outstanding

10-Q filing | 17.0M shares outstanding

10-Q filing | 17.0M shares outstanding

10-Q filing | 17.0M shares outstanding

10-K filing | 17.0M shares outstanding

S-3 filing: This S-3 filing relates to the proposed resale of common stock issuable upon exercise of pre-funded warrants by selling stockholders.

S-3 filing: The filing is an S-3 registration statement for the potential offering of up to $150,000,000 of common stock, preferred stock, debt securities, and/or warrants.

10-Q filing | 16.8M shares outstanding

10-Q filing | 10.9M shares outstanding

S-3 filing: This S-3 filing registers the resale of common stock and warrants by selling stockholders; the company will not receive any proceeds from the sale of these securities.

8-K filing: AcelRx Pharmaceuticals, Inc. completed a private placement on July 20, 2023, issuing 5,340,591 shares of common stock, pre-funded warrants for 2,012,356 shares, Series A warrants for 7,352,947 shares, and Series B warrants for 7,352,947 shares, resulting in gross proceeds of approximately $10.0 million. ($10.0M proceeds)

10-Q filing | 10.9M shares outstanding

10-K filing | 8.2M shares outstanding

8-K filing: AcelRx Pharmaceuticals, Inc. entered into a securities purchase agreement for the issuance and sale of common stock, pre-funded warrants, and common warrants, with aggregate gross proceeds expected to be approximately $7.5 million. ($7.5M proceeds)

S-3 filing: This S-3 filing relates to the proposed resale of common stock issuable upon the exercise of a warrant held by Lincoln Park Capital Fund, LLC. The company will not receive any proceeds from the sale of these shares.

10-Q filing | 7.4M shares outstanding

8-K filing | Stock split 1-for-20 | Outstanding: 147,209,065 → 7,360,453

10-Q filing | 147.2M shares outstanding

10-Q filing | 145.6M shares outstanding

S-3/A filing: This S-3/A filing relates to the proposed resale from time to time by the selling stockholders of up to 11,017,058 shares of common stock and up to $26.0 million of contingent consideration payable in cash or common stock at our option, upon the achievement of regulatory and sales-based milestones.

S-3 filing: This is an S-3 filing for the resale of up to 11,017,058 shares of common stock by selling stockholders and up to $26.0 million of contingent consideration payable in cash or common stock.

10-K filing | 136.8M shares outstanding

10-Q filing | 119.3M shares outstanding

8-K filing: AcelRx Pharmaceuticals, Inc. entered into a securities purchase agreement for the issuance and sale of 17,500,000 shares of common stock and warrants to Armistice Capital and Rock Springs Capital. ($14.0M proceeds)

10-Q filing | 119.2M shares outstanding

10-Q filing | 119.1M shares outstanding

10-K filing | 98.8M shares outstanding

8-K filing: AcelRx Pharmaceuticals, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. for a public offering of 14,500,000 shares of common stock at $1.7625 per share, with an option for the underwriter to purchase an additional 2,175,000 shares. ($25.56M proceeds)

8-K filing: AcelRx Pharmaceuticals, Inc. completed an offering of 8,333,333 shares of common stock at $1.20 per share, resulting in gross proceeds of $10 million. ($10.0M proceeds)

10-Q filing | 90.5M shares outstanding

10-Q filing | 80.9M shares outstanding

8-K filing: The Company entered into a securities purchase agreement with Armistice Capital and Rock Springs Capital for the issuance and sale of 9,433,962 shares of common stock at $1.06 per share, resulting in gross proceeds of approximately $10 million. ($10.0M proceeds)

S-3 filing: The company is filing an S-3 to register the offering of up to $150,000,000 of common stock, preferred stock, and debt securities.

POS AM filing: This is a Post-Effective Amendment to deregister all shares of Common Stock previously registered due to termination of the Merger Agreement.

10-Q filing | 80.8M shares outstanding

10-K filing | 80.4M shares outstanding